ANROAlto Neuroscience, Inc.vs its industry peers
A metric-by-metric comparison of Alto Neuroscience, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANROThis | $1.2B#4 | — | 5.4x#3 | — | — | -2.9%#3 | — | -28.8%#3 | — | — | 664.8%#1 | — |
| HROW | $1.3B#1 | — | 84.4x#5 | 4.7x#2 | 36.4%#1 | 70.6%#2 | 11.2%#2 | -33.8%#4 | 13.2%#2 | 6#1 | -20.2%#4 | — |
| OMER | $1.3B#2 | 10.0x#1 | — | 17.0x#3 | -34.0%#3 | 97.9%#1 | -166.4%#3 | — | -151.8%#4 | — | — | — |
| AKTS | $1.2B#3 | — | 2.5x#2 | — | — | — | — | 0.0%#2 | — | — | — | — |
| SVRA | $1.1B#5 | — | 7.4x#4 | 4109.2x#4 | — | -23.9%#4 | -48072.8%#4 | -82.7%#5 | -93.6%#3 | — | 41.8%#2 | — |
| AMPH | $1.0B#6 | 14.2x#2 | 2.3x#1 | 1.4x#1 | -1.7%#2 | -38.5%#5 | 19.5%#1 | 22.0%#1 | 13.2%#1 | 5#2 | -11.1%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice